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The suppression of the immune system creates a permissive environment for develop-
ment and progression of cancer. One population of immunosuppressive cells that have
become the focus of intense study is myeloid derived suppressor cells (MDSCs), immature
myeloid cells able to induce immune-escape, angiogenesis, and tumor progression.
Two different subpopulations have been identified and studied: granulocytic and mono-
cytic MDSCs, with a different immunophenotype and immunosuppressive properties.
Recently, an accumulation of both Gr-MDSCs and Mo-MDSCs cells has been found in
the peripheral blood of chronic myeloid leukemia (CML) patients. They are part of the
tumor clone showing BCR/ABL expression. Imatinib therapy decreases both MDSCs and
arginase 1 levels to normal ones. This review will focus on actual knowledge for human
MDSCs and their immunosuppressive activity in CML patients, with a critical attention to
comparison of Gr-MDSCs and polymorphonuclear cells (PMNs). We will then suggest the
monitoring of MDSCs in patients who have discontinued tyrosine kinase inhibitors (TKIs)
therapy to evaluate if their increase could correlate with disease relapse.
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Introduction
The research on myeloid derived suppressor cells (MDSCs) has become the focus of intense
study in recent years. For many years, the studies on MDSCs in cancer have been driven by
murine experiments where they are described as CD11b/Gr-1 double-positive cells (1). The Gr-1
antigens Ly-6G and Ly-6C distinguish the twomainMDSC subtypes, granulocytic (Gr-MDSCs) and
monocytic (Mo-MDSCs) ones, respectively (2). Because the Gr-1 antigen is not expressed on human
Gr-MDSCs, other markers have been employed. Today, there is no unequivocal immunoprofiling
to identify human MDSCs in cancer patients. Different combinations of antigens have been used
including CD33, CD11b, CD14, CD15, CD66b, Lin, and HLADR (3, 4). Nevertheless, human Mo-
MDSCs are mostly identified as CD14+ cells with negative or low expression of HLADR. Mo-
MDSCs express also high levels of CD11b and CD33 antigens. Human Gr-MDSCs are usually
defined as CD66b+CD11b+CD15+HLADR- cells and display an intermediate expression of CD33
and a variable expression of CD11b, depending on their maturation stage (1, 5). A third subtype
of MDSCs includes the CD34+ fraction (CD11b+CD33+CD14-HLADR-CD34+ cells) defined as
immature myeloid cells (IMCs) (6, 7).
Myeloid derived suppressor cells are myeloid cells characterized by their immature state and,
most importantly, by their ability to suppress immune system, especially T cell proliferation and
activity (8). MDSCs could suppress proliferation and T cell immunological function in patients with
different cancers (9–13). Gr-MDSCs and Mo-MDSCs can inhibit CD4+ effector T cells through
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 1071
Giallongo et al. MDSC in chronic myeloid leukemia
different mechanisms (2, 14). MDSCs inhibit immune system by
multiple mechanism, mostly through inhibition of T cell activa-
tion and expansion. Among others, the first identified were the
upregulation of nitric oxide synthase 2 (NOS2), reactive oxygen
species (ROS), and overexpression of arginase 1 (15, 16). The
upregulation of NOS2 and arginase1 leads to a deficiency of -
arginine, an amino acid indispensable for function and prolifer-
ation of T lymphocytes and for CD3ζ-chain expression of the T
cell receptor (17, 18). Furthermore, NOS2 activity generates nitric
oxide (NO), ROS, and peroxynitrate. Therefore, its upregulation
leads to an accumulation of NO that suppresses T cell activity
through the inhibition of IL-2 pathway (19). In addition, the
increased peroxynitrate production results in the nitration of the
CD8 TCR with inhibition of CD8+ T cell activity (20).
More recently, several other mechanisms were identified,
including upregulation of cyclooxigenase-2 and prostaglandin E2
(21), induction of regulatory T cells (22–24), production of TGF-
β (25), depletion of cystein (26), and downregulation of T cell
-selectin expression (27). Also, inhibition of NK function by
MDSCs via downregulation of the activating receptor NKG2Dhas
been reported (1, 28). The specific mechanisms used by MDSCs
are microenvironment-dependent.
Despite decreased plasma arginine concentrations have been
observed in patients with an immunosuppressive state, some
authors have failed to show any detectable benefits of -arginine
supplementation (29). As MDSCs utilize different mechanisms
to immunosuppress innate and adaptive anti-tumor immunity,
targeting directly MDSCsmight be a better approach to overcome
MDSC-dependent immune dysfunction.
This review summarizes the current knowledge for human
MDSCs and their immunosuppressive function in chronic
myeloid leukemia (CML). We will also provide a critical compari-
son of Gr-MDSCs and PMNs showing a strong potential immune
escape mechanism in CML patients created by myeloid cells (6).
Finally, we will discuss potential application of MDSCs for the
monitoring of MDSCs in patients who have discontinued TKIs
therapy, in order to evaluate if their levels could correlate with
disease relapse (6).
CML and Immune Dysfunction
Chronicmyeloid leukemia is characterized by the reciprocal chro-
mosomal translocation t(9;22)(q34;q11), leading to the formation
of the Philadelphia chromosome. This encodes the constitutively
active Bcr-Abl tyrosine kinase, which profoundly affects prolifer-
ation, apoptosis, and cell adhesion signaling pathways (30). The
majority of patients are diagnosed in chronic phase (CP), showing
an expansion of myeloid lineage cells that are maintained by a
small subset of CD34+/CD38 – leukemic stem cells (LSCs) (31).
Refractoriness of these LSCs to therapy may result in progression
to blast crisis (BC), characterized by differentiation arrest and
a disease more akin to that of an acute leukemia. The advent
of TKIs has drastically changed the treatment outcome of CML.
Imatinib was the first TKI approved, and has been considered
the standard of care for more than a decade. Although the ther-
apy with Imatinib is considered a major advance in oncology,
a significant group of patients still develop drug resistance (32).
Second generation compounds, namely Dasatinib and Nilotinib,
are highly effective in those who fail Imatinib as well as in newly
diagnosed patients (33).
In CML, like in other malignancies, the immune system is
impaired favoring immune escape of the malignant cells (6).
CD4+ T cells, central components of effective immune response
against tumor, appear to be anergic to the leukemia cells (34, 35),
and show low levels of TCR-ζ chain expression compared with T
cells of healthy subjects (36). The regulation of immune activation
has also been found to be altered in CML. Bachy et al. (37) showed
that regulatory T cells (T-reg) are significantly increased in CML
patients with intermediate or high-risk Sokal scores compared to
the low risk (LR) patients. CML patients also express higher levels
of programed death receptor ligand 1 (PD-L1) on myeloid cells
(including also CD34+ stem cells), compared to control subject
cells, and its receptor PD-1 is expressed on T-cells. By binding to
the inhibitory receptor PD-1 on T-cells, PD-L1 is able to suppress
the T-cell effector functions (38). The same study showed that the
interruption of PD-1/PD-L1 interaction enhanced T cell function.
Already there is a promising evidence indicating that some
CML patients can stop Imatinib treatment without suffering
disease relapse after achieving a complete molecular response
(CMR), although they have a minimal amount of residual
leukemia cells left (39, 40). This implies that the immune system
is able to restrain the tumor cell expansion, and that the TKI
therapy has at least restored the function of the normal immune
system or probably in some cases further strengthened it (6).
Unfortunately, molecular relapse is observed after cessation of
Imatinib in 61–66% of CML patients, previously in CMR (41, 42),
presumably due to the reactivation of dormant CML LSCs that
are resistant to TKI-induced leukemic cell ablation. Thus, current
research efforts aim to develop additional therapies to target these
TKI-refractory CML LSCs.
MDSCs Expansion in CML
As in a variety of cancers, MDSCs play a central role in anti-
tumor immune response in hematological malignances (7, 43–
48), but little is reported on the role of MDSCs in CML. Chris-
tiansson et al. investigated for the presence of MDSCs and Arg-1
in CML patients (38). Since Sokal high risk (HR) patients have an
increased risk of relapse after TKI treatment cessation (41), the
purpose of the authors was to understand the immune status of
Sokal HR and LR CML patients. The study showed an increase
of the Gr-MDSCs subset (defined as CD11b+CD14-CD33+) that
was limited to HR patients. In fact, in their cohort of CML,MDSC
levels appeared similar in the CML patient group compared to
control individuals. Dividing patients into HR and LR groups, the
HR patients showed statistically significant higher MDSC levels
both in respect to LR group and control individuals. Also, the
expression of arginase 1 as well as its plasma levels were increased
in the patients compared to healthy controls. The same authors
showed that CD34+ cells (mostly tumor cells) of CML patients
expressed MDSC markers; however, MDSCs were identified on
both CD34- and CD34+ cell populations. The effect of TKIs on
MDSCs and arginase 1 was not evaluated in the Christiansson’s
study. However, if the authors demonstrated higher levels of
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MDSCs in HR patients compared to LR ones, the correlation
with worse prognosis for CML needs to be confirmed in a larger
study. Furthermore, functional suppressive assays, essential for
the evaluation of MDSCs, due to the lack of a unique surface
markers signature for their identification (49) were also miss-
ing in this study. In addition, it should be underlined that in
the Christiansson’s study, the evaluation of MDSC phenotype
was conducted in cryopreserved samples, and some studies have
shown that separation of Gr-MDSCs from frozen samples leads to
a significant decrease in MDSCs viability and function (6, 50).
Recently, we have analyzed both Gr-MDSCs and Mo-MDSCs
subsets in fresh samples of CML patients at diagnosis and fol-
lowing them during treatment with Imatinib (6). Representative
flow cytometry analysis for one patient and one healthy donor is
shown in Figure 1. Analyzing by flow cytometry the percentage
ofMDSCs cells identified asCD11b+CD33+CD14-HLADR-(Gr-
MDSCs) and CD14+HLADR-(Mo-MDSCs), we discovered that
both subpopulations were significantly increased in patients at
diagnosis compared to healthy subjects and decreased to nor-
mal levels after Imatinib therapy. No correlation was observed
between the percentage ofMDSCs and age, nor with leukocytosis,
Sokal risk, or the response to TKI therapy. Our set comprised only
three patients who were resistant to Imatinib; they showed very
high percentages of MDSCs, although not the highest observed.
Using magnetic separation, Gr-MDSCs and Mo-MDSCs were
analyzed for BCR/ABL expression by real-time polymerase chain
reaction (PCR). Both subpopulations showed the oncoprotein
expression confirming that they are part of the tumor clone. The
series of our study included few patients belonging to HR group,
and therefore we could not verify if MDSC levels correlate with
Sokal risk.
Expression of arginase 1 and its circulating levels in the serum
resulted higher in patients at diagnosis in respect to healthy con-
trols and decreased during Imatinib treatment. Furthermore, the
percentage of Gr-MDSCs correlated with arginase 1 protein levels
in the serum of patients at diagnosis.
MDSCs Promote the Expansion of T-reg
Immunosuppressive CD4+CD25hiFoxP3+T-reg cells play a cen-
tral role in the induction of tolerance to cancer antigens. They
include both thymus-derived natural T-reg (nT-reg) and locally
induced T-reg (iT-reg) cells. Both subpopulations employ contact-
dependent and contact-independentmechanisms to constrain the
activation of effector T cells (51, 52). Naive CD4+CD25- T cells
can be converted into iT-reg cells after exposure to antigen in
the presence of cytokines such as TGF-β or IL-10 (53, 54). It
has been demonstrated that the administration of progenipoietin-
1 (a synthetic granulocyte colony-stimulating factor/Flt-3 ligand
molecule) to donors in an allogeneic bonemarrow transplantation
model generated MDSCs, which upon transfer suppressed the
initiation of graft-versus-host disease (GVHD) in recipients by
inducing a population of MHC class II-restricted, interleukin 10
(IL-10)-producing T-reg (55). Similarly, in a colon carcinoma
murine model, MDSCs either generated or expanded the pool
of CD4+CD25+FOXP3+ T-reg (22). Moreover, using the A20
FIGURE 1 | Representative data of circulating Gr-MDSCs and Mo-MDSCs cells in PB from one healthy donor (HD) and one CML patient at diagnosis.
Flow cytometry analysis was performed with gates set on either CD11b+CD33+CD14-HLADR- or CD14+HLADR- cells populations.
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FIGURE 2 | Frequency of circulating T-reg cells in PB was calculated
by cytometric analysis with gates set on CD4+ cells, and the results
presented as the percentage of CD25+Foxp3+cells in CD4+ cells.
The figure shows the correlation of the percentages of Gr-MDSCs cells and
T-reg in PB from CML patients at diagnosis.
B-cell lymphoma model, Serafini and colleagues showed that
the expansion of a preexisting pool of T-reg can be mediated
by MDSCs (23). They described MDSCs as tolerogenic antigen
presenting cells with ability in antigen uptake and presentation to
tumor-specific T-reg. MDSC-mediated T-reg induction required
arginase, but was TGF-β independent. Inhibition of MDSC func-
tion abrogated T-reg proliferation and tumor-induced tolerance.
Many authors provide evidence of an increased frequency of T-
reg cells in CML patients at diagnosis in association with higher
Sokal scores and higher levels of BCR-ABL transcripts, indicating
that an immune responsemay be important in the control of CML
(37, 56). In addition, T-reg number was significantly lower in
patients with CPCML versus the accelerated and blast phases, and
was significantly lower in patients with CMR compared to those
patients without CMR (57). To understand if there is a correla-
tion in CML patients between MDSCs and T-reg frequency, we
investigated the levels of both circulating lymphoid and myeloid
subpopulations founding a direct correlation between the per-
centages of T-reg and Gr-MDSCs at diagnosis (Figure 2) (6). The
percentage of T-reg cells was higher in patients at diagnosis com-
pared to healthy donors and decreased to the normal levels after
Imatinib treatment, confirming the correlation with the levels of
Gr-MDSCs.
Gr-MDSCs and Mature Neutrophils Display
Immunosuppressive Properties in CML
Patients
Neutrophils take action to innate and adaptive immunity, but
their role in cancer has been unclear. Munder et al. demon-
strated that arginase activity is specific of human circulating
polymorphonuclear cells (PMNs) (58). The enzyme localizes to
the azurophil granules and, once released, specifically depletes
extracellular arginine inducing profound suppression of various
T cell functions (59). Activated PMNs producing arginase1 has
been found in the peripheral blood and placenta of pregnant
women, suggesting that arginase 1 is important in suppressing the
maternal immune responses against the fetus (60). Granulocyte
activation and degranulation have been found in abscesses of
patients where pus (which contains a large number of activated
PMNs) suppresses T cell proliferation and activity (58). Therefore,
although PMNs are important in controlling acute infections, they
act inhibiting T cell activity in a chronic inflammatorymicroenvi-
ronment where malignant cells are not eliminated. Since arginase
1 has a central role in T cell suppression in both Gr-MDSCs and
PMNs in several cancers (61–63), especially in CML characterized
by an expansion of granulocytes, it is important to compare Gr-
MDSCs with autologous PMNs. First, we demonstrated a signif-
icant overlap between Gr-MDSCs and PMNs using the CML as
model. AsCMLGr-MDSCs, CMLPMNswere able to significantly
suppress T cell proliferation; no inhibition was observed after
incubation with Gr-MDSCs and PMNs from healthy donors (6).
Both arginase 1 protein and its enzymatic activity were higher
in CML PMNs than autologous Gr-MDSCs, demonstrating a
critical role of CML PMNs in the tumor microenvironment. All
functional experiments were performed using fresh blood.
Even if Gr-MDSCs and PMNs are phenotypically and function-
ally different myeloid subsets, they share many common features
(6). First, Gr-MDSCs have similar functions to PMNs such as
immunosuppression, angiogenesis (64, 65), invasion, and metas-
tasis (66, 67). As PMNs (63), MDSCs acquire strong immuno-
suppressive activity after activation (68). Furthermore, human
Gr-MDSCs are identified by a set of antigens (CD11b, CD14,
CD15, CD33, CD66b, CD16, and HLADR), which are well-
established markers for PMNs (3, 4). Therefore, the significant
overlap between Gr-MDSCs and PMNs concerns both their activ-
ity and their immunophenotype. Human MDSCs from renal cell
carcinoma (RCC) patients has been described as a subpopulation
of activated PMN cells expressing markers of mature activated
granulocytes, including high levels of CD66b and CD11b and low
levels of CD62L and CD16 (10, 69). These cells degranulated and
released arginase 1, resulting in low levels of -arginine in plasma.
Therefore, in RCC patients, activation of normal PMNs induces
phenotypic and functional changes similar to MDSCs. Despite
the low percentage of IMCs identified as CD11b+CD33+CD14-
HLADR-CD34+ cells, CML Gr-MDSCs are more immature cells
compared to autologous PMNs, and showed lower levels of expres-
sion of CD11b, CD15, and CD16, and lower Arg1 expression and
activity (6).
In contrast to conventional PMNs collected from the normal
density neutrophil fraction on top of red cells, Gr-MDSCs are
isolated from the mononuclear cell fraction in density gradient of
blood (Figure 3). In fact, Gr-MDSCs are defined as low-density
immature cells with neutrophil-like morphology (1, 70). Whether
Gr-MDSCs are specialized subsets of neutrophils or originate
through an altered process of granulopoiesis is still unclear (3).
The recent observations that Mo-MDSCs can differentiate into
Gr-MDSCs in tumor-bearing mice and in patients with multiple
myeloma have further complicated the scenario (71). Since tumor
associated PMNs and Gr-MDSCs seem to represent functional
states of cells originating from the same cell type (1), in every
study it may be important a careful comparison of Gr-MDSCs and
PMNs from the same diseased individuals.
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FIGURE 3 | Isolation of Gr-MDSCs after blood centrifugation over
density gradient. Mature neutrophils typically sediment on top of red cells,
whereas mature activated neutrophils and immature granulocytes, as well as
Gr-MDSCs, sediment within the mononuclear cell fraction.
Concluding Remarks
Among immunosuppressive mechanisms, MDSCs play a central
role in anti-tumor immune response in hematological malignan-
cies including CML.
Therapy with TKIs has changed the course of the CML, but
these drugs are not able to eradicate CML clone (72, 73). Rohon
et al. (74) evaluated the immunophenotype profiling of lym-
phocytes from CML patients during therapy with Imatinib, and
found that the immunoprofile resembled healthy subjects, while
Mustjoki et al. (75) showed that treatment with dasatinib resulted
in a favorable outcome in Ph+ leukemia with clonal expansion of
NK or T cells. The recent study byMahon et al. (41) demonstrated
that approximately 60% of CML patients who stopped therapy
with Imatinib after a period of durable CMR relapsed molecularly
within the next 6months. Another study reported that patients
who had maintained a stable CMR for at least 2 years with Ima-
tinib therapy stopped therapy, but DNA PCR found CML cells
again (76). Therefore, in these patients, the immune system is
important in maintaining complete remission. In addition, it has
been found that NK are important in controlling the leukemic
cell growth; in fact, increased levels of NK cell seem to correlate
with the successful Imatinib cessation (77). All these observations,
together with the finding of BCR/ABL transcripts in some healthy
subjects (78), support the idea that in some patients the immunity
could exert an immune surveillance against cancer cells, while an
inhibition of this control may lead to a permissive environment
for development and progression of leukemia. In this scenario,
we hypothesize that Gr-MDSC could play a significant role in
favoring the development of CML and its progression. Gr-MDSCs
are in fact increased in all CML patients at diagnosis and their
level decrease after an effective treatment. We have demonstrated
that, in CML, Gr-MDSCs are characterized by a high production
of Arginase and it, likely that, is through this protein that they
are able to suppress the activity of T lymphocytes. In fact, Gr-
MDSCs from CML patients are able to suppress normal lympho-
cytes activation with a dose-dependent activity. In addition, the
suppressive cell population known as T-reg is increased in CML
patients at diagnosis and is directly correlated with the amount
of MDSC. We have also demonstrated that in CML, the cells
that have a MDSC phenotype harbor the genetic defect charac-
teristic of CML, and therefore they at least in part belong to the
neoplastic clone. This observation further underlines the lack of
knowledge on the mechanisms of MDSC development in CML
and other hematological neoplasms. Do these cells derive from
myeloid cells (normal or neoplastic) that are induced to become
immunosuppressive by cytokines produced by tumors? Is this a
special immunosuppressive cell population directly produced by
bone marrow in response to a neoplastic stimulus?
In addition, it seems clear that there is a significant overlapping
between MDSC and neutrophils and, in our studies, we have
found that even mature granulocytes from CML may exert a
strong immunosuppressive action on T lymphocytes.
Future studies will be oriented at evaluating the reasons for
the development of MDSC, the identification of the cytokines
involved in this process, and the possible mediation of other
population such as the mesenchymal cells in the induction of the
MDSC phenotype. Further study will be also conducted in order
to clarify the immunological features of CML patients who relapse
after Imatinib discontinuation. In this context, the monitoring of
MDSCs in CML patients who have discontinued therapy could be
of interest in order to evaluate if their increase could correlate with
the restarting of the leukemic growth.
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